Method for treating infectious diseases with isothiocyanate functional compounds

• US 10,335,387 B2
• Filed: 07/02/2018
• Issued: 07/02/2019
• Est. Priority Date: 07/26/2012
• Status: Active Grant

• Current Assignee: The William M. Yarbrough Foundation
• Original Assignee: The William M. Yarbrough Foundation
• Inventors: Silver, Michael E.
• Primary Examiner(s): Henley, III, Raymond J
• Application Number:
  US16/025,640
• Publication Number:
  US 20180311202A1
• Time in Patent Office: 365 Days
• Field of Search: 514562, 514629, 514638
• CPC Class Codes: A61K 31/16 Amides, e.g. hydroxamic acids
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/26 Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A method for treating an infectious disease, including the step of administering an isothiocyanate functional surfactant to a patient having an infectious disease. In one embodiment, the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

Claims

1. A method for treating an infectious disease, comprising the step of:

administering an isothiocyanate functional surfactant to a patient having an infectious disease.

2. The method according to claim 1, wherein the infectious disease comprises at least one of a bacterial infection, a fungal infection, a prion infection, a protozoan infection, and a viral infection.

3. The method according to claim 2, wherein the bacterial infection comprises at least one of actinomycosis, anthrax, bejel, boutonneuse fever, brucellosis, brucellosis spondylitis, bubonic plague, campylobacteriosis, carrion disease, cat scratch disease, cervicitis, chancroid, chlamydia, lymphogranuloma venereum, cholera, clostridial infection, dysentery, shigellosis, epididymitis, erysipelothrix infection, glanders, gonorrhea, granuloma inguinale, gumma, legionnaire disease, leprosy, leptospirosis, listeriosis, lyme disease, melioidosis, methicillin-resistant staphylococcus aureus, nocardiosis, paratyphoid fever, pharyngitis, plague, pneumonia, proctitis, pseudotuberculosis, psittacosis, q-fever, rat-bite fever, Reiter syndrome, relapsing fever, rheumatic fever, Rocky Mountain spotted fever, salmonellosis, scarlet fever, scrofula, scrub typhus, septicemia, shigellosis, staphylococcus infection, streptococcal pharyngitis, streptobacillary fever, syphilis, tetanus, tonsillitis, toxic shock syndrome, trench fever, tuberculosis, tularemia, typhoid fever, typhus, urethritis, vaginitis, vesiculitis, vulvitis, Waterhouse-Friderichsen syndrome, whooping cough, yaws, yersiniosis, gram positive bacterial infections, gram negative bacterial infections, aerobic bacterial infections, and anaerobic bacterial infections.

4. The method according to claim 2, wherein the fungal infection comprises at least one of aspergillosis, blastomycosis, candidiasis, chromoblastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, pharyngitis, pneumonia, sporotrichosis, thrush, urethritis, vaginitis, and vulvitis.

5. The method according to claim 2, wherein the protozoan infection comprises at least one of avian malaria, blackwater fever, chagas disease, coccidiosis, leishmaniasis, malaria, oriental sore, sleeping sickness, toxoplasmosis, trichomoniasis, and trypanosomiasis.

6. The method according to claim 2, wherein the viral infection comprises at least one of acquired immune deficiency syndrome, bird flu, Borna disease, chikungunya fever, chickenpox, Colorado tick fever, common cold, cowpox, dengue, distemper, dysentery, Ebola, herpangina, herpes simplex, herpes zoster, human immunodeficiency virus, influenza, measles, monkeypox, mumps, pappataci fever, pharyngitis, pneumonia, polio, proctitis, pseudorabies, Rift Valley fever, roseola infantum, rubella, smallpox, swine flu, tonsillitis, viral hemorrhagic fever, vulvitis, West Nile virus disease, yellow fever, and Zika fever.

7. The method according to claim 2, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.

8. The method according to claim 2, wherein the isothiocyanate functional surfactant comprises a lysine derivative, wherein the lysine derivative comprises an α

-nitrogen and a ε

-nitrogen, and wherein an alkyl and/or alkanoyl substituent comprising at least approximately 8 carbon atoms is associated with the α

-nitrogen, and further wherein at least one isothiocyanate functional group is associated with the ε

-nitrogen.

9. The method according to claim 2, wherein the isothiocyanate functional surfactant is represented by the following chemical structure:

10. The method according to claim 2, wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

11. The method according to claim 2, wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

12. The method according to claim 2, wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

13. The method according to claim 2, wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

14. The method according to claim 2, wherein the protonated form of the isothiocyanate functional surfactant is represented by at least one of the following chemical structures:

15. The method according to claim 2, wherein the isothiocyanate functional surfactant is represented by the following chemical structure:

16. The method according to claim 2, wherein the isothiocyanate functional surfactant is represented by the following chemical structure:

17. The method according to claim 2, wherein the isothiocyanate functional surfactant is administered to the patient at least one of orally, intravenously, intramuscularly, intrathecally, cutaneously, subcutaneously, transdermally, sublingually, buccally, rectally, vaginally, ocularly, otically, and nasally.

18. The method according to claim 17, wherein the amount of isothiocyanate functional surfactant topically administered to the patient ranges from approximately 0.5 nmol/cm2 to approximately 10 μ

mol/cm2.

19. The method according to claim 1, wherein the patient is a mammal.

20. The method according to claim 19, wherein the mammal is a human.